GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scancell Holdings PLC (LSE:SCLP) » Definitions » EV-to-Revenue

Scancell Holdings (LSE:SCLP) EV-to-Revenue : (As of Apr. 29, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Scancell Holdings EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Scancell Holdings's enterprise value is £95.92 Mil. Scancell Holdings's Revenue for the trailing twelve months (TTM) ended in Oct. 2023 was £0.00 Mil. Therefore, Scancell Holdings's EV-to-Revenue for today is .

The historical rank and industry rank for Scancell Holdings's EV-to-Revenue or its related term are showing as below:

LSE:SCLP' s EV-to-Revenue Range Over the Past 10 Years
Min: 14.25   Med: 17.2   Max: 25.86
Current: 18.2

During the past 13 years, the highest EV-to-Revenue of Scancell Holdings was 25.86. The lowest was 14.25. And the median was 17.20.

LSE:SCLP's EV-to-Revenue is ranked worse than
66.34% of 1034 companies
in the Biotechnology industry
Industry Median: 7.69 vs LSE:SCLP: 18.20

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-29), Scancell Holdings's stock price is £0.096. Scancell Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Oct. 2023 was £0.00. Therefore, Scancell Holdings's PS Ratio for today is .


Scancell Holdings EV-to-Revenue Historical Data

The historical data trend for Scancell Holdings's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scancell Holdings EV-to-Revenue Chart

Scancell Holdings Annual Data
Trend Apr14 Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 24.24

Scancell Holdings Semi-Annual Data
Apr14 Oct14 Apr15 Oct15 Apr16 Oct16 Apr17 Oct17 Apr18 Oct18 Apr19 Oct19 Apr20 Oct20 Apr21 Oct21 Apr22 Oct22 Apr23 Oct23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 24.24 -

Competitive Comparison of Scancell Holdings's EV-to-Revenue

For the Biotechnology subindustry, Scancell Holdings's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Scancell Holdings's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scancell Holdings's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Scancell Holdings's EV-to-Revenue falls into.



Scancell Holdings EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Scancell Holdings's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=95.918/0
=

Scancell Holdings's current Enterprise Value is £95.92 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Scancell Holdings's Revenue for the trailing twelve months (TTM) ended in Oct. 2023 was £0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Scancell Holdings  (LSE:SCLP) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Scancell Holdings's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=0.096/0
=

Scancell Holdings's share price for today is £0.096.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Oct. 2023 was £0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Scancell Holdings EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Scancell Holdings's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Scancell Holdings (LSE:SCLP) Business Description

Traded in Other Exchanges
Address
Sanders Road, Unit 202, Bellhouse Building, Oxford Science Park, Oxford, GBR, OX4 4GD
Scancell Holdings PLC is engaged in the discovery and development of novel vaccines for the treatment of cancer. The company is exploiting the unrivalled potential of the immune system to seek out and destroy cancer using two proprietary immuno-oncology platforms: ImmunoBody and Moditope. Its potent innovative DNA-based ImmunoBody therapies generate ultra-high avidity T cell responses that target and eliminate cancerous tumors. Its Moditope platform technology overcomes the immune suppression induced by tumors themselves, allowing activated T cells to seek out and kill tumor cells that would otherwise be hidden from the immune system.

Scancell Holdings (LSE:SCLP) Headlines

No Headlines